real peptides FAQ

Anti-aging & longevity peptides target processes that unfold over months to years. Telomere maintenance, senescent cell clearance, and mitochondrial biogenesis don't produce overnight changes. Biomarker tracking is essential: measure baseline IGF-1 before starting GH secretagogues, inflammatory markers (IL-6, TNF-alpha) before immune modulators, and DNA methylation age before extended protocols. Subjective improvements in recovery, sleep quality, and cognitive function typically precede measurable biomarker shifts by 4–8 weeks. If zero changes appear after 12 weeks at therapeutic dosing, the peptide may not be addressing your rate-limiting aging pathway. Not every intervention works equally across all biological aging profiles.

Administer SS-LUP-332 to already-trained subjects and the magnitude of effect diminishes significantly. Studies using exercise-trained rodents found that SS-LUP-332 produced only 10–15% additional improvement in running capacity compared to 50–70% in sedentary animals—the trained muscle tissue already expresses elevated PPARδ, PGC-1α, and mitochondrial proteins, reducing the transcriptional headroom available for further upregulation. Gene expression analysis confirms this ceiling effect: SS-LUP-332 increased PGC-1α mRNA 2.5-fold in sedentary muscle but only 1.3-fold in trained muscle. This dose-response relationship mirrors exercise itself—the first month of training produces dramatic gains; subsequent months yield smaller incremental adaptations as the muscle approaches its genetic and metabolic ceiling.

Switch to a preservative-free formulation or reduce dose frequency temporarily. Some compounded VIP nasal sprays contain benzalkonium chloride or other preservatives that irritate sensitive nasal mucosa, especially in CIRS patients with multiple chemical sensitivities. Preservative-free VIP formulations are available through compounding pharmacies and eliminate this issue in most cases. If irritation persists even with preservative-free VIP, reduce dosing to twice daily for one week to allow nasal tissue adaptation, then gradually increase back to four times daily. Nasal irrigation with saline 30 minutes before VIP administration also reduces irritation by clearing mucus and hydrating tissue.

Thymalin is the evidence-backed choice. It restores thymic epithelial cell function and increases naive T-cell output, which is essential for clearing latent viral infections (EBV, CMV, HSV) that persist when immune surveillance declines. Clinical studies show T-cell count increases within 4–8 weeks. Combine with anti-inflammatory peptides like KPV to reduce excessive immune activation that can cause collateral tissue damage during clearance.

Target mitochondrial dysfunction directly with SS-31 or MOTS-C. Cardiopulmonary exercise testing (CPET) should confirm reduced VO2 max and elevated lactate threshold before initiating protocols—these are objective markers of impaired oxidative phosphorylation. SS-31 research dosing ranges from 5–40mg subcutaneous daily; MOTS-C uses 5–10mg subcutaneous 2–3 times weekly. The mechanism—stabilizing cardiolipin and improving electron transport chain efficiency—takes 4–8 weeks to manifest as increased exercise tolerance and reduced post-exertional malaise. Serial CPET at 8–12 weeks provides objective outcome data.

Discard immediately. Particulate formation indicates protein aggregation, precipitation, or bacterial contamination, any of which renders the solution unsuitable for research use. Even if the majority of the solution remains clear, the presence of visible particles signals that peptide degradation has begun and the amino-acid sequence is no longer intact. Bacteriostatic water extends reconstituted peptide stability to 28 days under ideal conditions (2–8°C, amber vial, no freeze-thaw cycles), but this assumes sterile reconstitution technique and zero contamination. Particulate matter is a hard stop.

Limit analysis to qualitative trends rather than quantitative dose-response if peptides underwent more than two freeze-thaw cycles. Peptide activity degrades progressively with each cycle due to ice crystal formation disrupting tertiary structure. Activity loss ranges from 15–40% per cycle depending on peptide sequence. For future studies, aliquot reconstituted peptides into single-use volumes immediately after preparation. Store aliquots at −80°C if available; standard −20°C freezers experience temperature fluctuations during defrost cycles that cause micro-thawing.

True recomposition at maintenance calories (zero net weight change while fat decreases and muscle increases) is biochemically difficult but achievable with precise peptide selection. The protocol requires compounds that enhance nutrient partitioning—shifting ingested calories toward muscle protein synthesis rather than fat storage. Research using MK-677 (a ghrelin mimetic) at 25 mg daily demonstrated this exact outcome: subjects maintained stable body weight over 16 weeks while DEXA scans showed 1.1 kg lean mass gain and 1.3 kg fat mass loss. The mechanism involves elevated IGF-1 driving muscle protein synthesis while increased growth hormone pulses enhance lipolysis during fasted periods. Maintenance recomposition requires higher protein intake (2.2–2.6 g/kg) and progressive resistance training—the peptides create the hormonal environment, but mechanical tension and amino acid availability are what actually build tissue.

Yes, but the mechanism shifts. At body fat levels below 12% (men) or 20% (women), the body's adaptive responses to caloric deficit become more aggressive—leptin drops sharply, ghrelin stays elevated longer, and thyroid output decreases to preserve remaining fat stores. GH secretagogues become particularly valuable at this stage because they maintain IGF-1 levels that would otherwise crash, preventing muscle catabolism even as fat loss slows. Research using ipamorelin in lean subjects (BMI 20–23) showed that lean mass was preserved even during 20% caloric deficits sustained for eight weeks, whereas control groups lost measurable muscle mass. The fat loss rate was slower than in higher-body-fat subjects, but the recomposition ratio (percentage of weight lost coming from fat vs muscle) was actually better—94% fat vs 6% lean compared to 85% fat vs 15% lean in subjects starting above 25% body fat.

Investigate immune recalibration compounds first—specifically Thymosin Alpha 1 or Thymalin. Research protocols typically begin with baseline cytokine profiling (IL-6, TNF-alpha, IFN-gamma) to confirm ongoing immune activation, then administer Thymosin Alpha 1 at 1.6mg subcutaneous twice weekly for 12–16 weeks. The mechanism targets dendritic cells and regulatory T-cell function, pathways that remain dysregulated long after bacterial clearance. Response markers include reduction in pro-inflammatory cytokines and improved CD4+/CD8+ ratios, measurable through serial blood draws at 4, 8, and 12 weeks.

Consider BPC-157 to address gut-brain axis disruption. Research suggests Borrelia infection compromises intestinal barrier integrity, increasing lipopolysaccharide (LPS) translocation into systemic circulation—driving both neuroinflammation and systemic cytokine activation. BPC-157 promotes angiogenesis and accelerates mucosal healing in the GI tract while modulating the vagus nerve signaling that connects gut inflammation to brain function. Typical research protocols use 250–500mcg subcutaneous daily for 4–8 weeks, with symptom tracking focused on both GI function (Bristol stool scale, abdominal pain scores) and cognitive clarity.

This likely reflects receptor downregulation rather than compound degradation. Chronic REV-ERB agonism can trigger compensatory upregulation of BMAL1 and other clock genes, attenuating the initial metabolic response. Consider implementing a dosing schedule with 48-hour washout periods between administrations, or reduce dose to 60–70% of the initial amount after day three. Our experience with circadian-modulating compounds shows that continuous daily dosing rarely maintains initial effect magnitude beyond one week without dose adjustment.

VIP shipping delivers to the address, but what happens after delivery determines viability. If you're shipping to a field research site, remote clinic, or location without immediate refrigeration access, coordinate delivery timing so someone retrieves the package within 30 minutes of arrival. Use portable coolers with ice packs as temporary storage (2–8°C) until you reach proper refrigeration. Real Peptides can also ship to a nearby pharmacy or medical facility with cold storage, then you retrieve it. Many compounding pharmacies accept peptide deliveries as a service. For extended remote work, consider lyophilised peptides only (never pre-mixed) and bring a portable 12V refrigerator rated for 2–8°C if mains power is unavailable.

Verify receptor expression in your cell line or tissue model first. If the target cells don't express KISS1R, exogenous kisspeptin won't produce a response regardless of dose. Next, confirm the peptide is reaching the target compartment: peptides >3 kDa don't cross cell membranes efficiently, so if you're studying an intracellular target, you need cell-penetrating peptide (CPP) conjugation or electroporation. Finally, check whether your readout is downstream enough. GnRH stimulates LH secretion within 30 minutes, but downstream effects like steroidogenesis take 4–6 hours. Measuring too early or too late in the signaling cascade produces false negatives.

TGF-β1 elevation is a hallmark of chronic mold illness and represents a distinct immunological pattern from acute cytokine storms. VIP is still first-line because it modulates the regulatory T-cell axis that controls TGF-β1 production, but expect slower response times. 12–16 weeks rather than 8–10. LL-37 is less useful here because TGF-β1 elevation isn't driven by bacterial LPS or secondary infection. Thymosin Alpha-1 remains valuable because TGF-β1 suppresses T-cell proliferation, and restoring T-cell function helps break the cycle. Consider pairing VIP with Thymosin Alpha-1 at standard doses and reassess TGF-β1 at week 12.

Discard the vial immediately—cloudiness or visible particles indicate aggregation, precipitation, or microbial contamination. Peptides are soluble in aqueous solution at physiological pH; cloudiness suggests the peptide has aggregated due to incorrect reconstitution pH, excessive agitation, or temperature shock (reconstituting with ice-cold water into a room-temperature vial). Aggregated peptides cannot bind receptors properly and may trigger immune responses in animal models. Always reconstitute slowly by injecting bacteriostatic water down the side of the vial, allowing it to dissolve passively without shaking—mechanical agitation disrupts hydrogen bonding and promotes aggregation.

Absolutely. Subcutaneous injection produces slower, sustained plasma levels compared to intravenous administration, which peaks rapidly and clears faster. Intranasal delivery bypasses first-pass metabolism and delivers peptides directly to the CNS via the olfactory bulb. Semax and Selank are commonly administered intranasally in research settings for this reason. Oral bioavailability is limited for most peptides due to proteolytic degradation in the GI tract; Dihexa is a rare exception with confirmed oral activity. Research design must match delivery route to the peptide's pharmacokinetics. We provide bioavailability and half-life data for every compound to inform protocol development.

VIP or Thymosin Alpha-1. Both address the immune dysregulation that drives most symptoms. If your primary symptoms are brain fog, fatigue, and exercise intolerance, start with Thymosin Alpha-1 because it targets T-cell and NK cell function, which affect energy and neurological clarity. If your primary symptoms are respiratory issues, gut dysfunction, or you have documented cytokine elevations, start with VIP because it directly modulates the inflammatory cascade. BPC-157 is powerful for gut healing but won't address immune dysfunction upstream. LL-37 is a secondary add-on, not a foundational intervention.

Reproductive toxicity data for SS-LUP-332 does not exist, so any use in breeding protocols, pregnancy models, or developmental studies is entirely exploratory. ERRγ is expressed in ovarian tissue, the uterus, and the placenta, and plays a role in estrogen signaling and mitochondrial function during embryogenesis. Until two-generation reproductive toxicity studies (OECD Test Guideline 416) are published, you cannot assume the compound is safe during gestation or lactation. If your study requires dosing during pregnancy, limit exposure to the first trimester equivalent in rodents (gestational days 0–6) and include detailed fetal morphology assessment, placental histology, and postnatal developmental milestones—or exclude breeding-age females entirely from the protocol until reproductive safety is established.

Discard the vial and order a replacement. VIP loses 20–40% bioactivity after 12 hours at ambient temperature due to methionine oxidation and peptide bond hydrolysis. The degradation is irreversible and there is no reliable way to quantify remaining potency without receptor-binding assays. Using compromised peptide introduces a confounding variable that invalidates experimental results, particularly in dose-response studies where reduced activity could be misinterpreted as biological effect rather than material failure. The cost of replacing a single 2mg vial ($85–$120) is negligible compared to the cost of repeating an entire study with failed controls.